Dr. Meekoo Dhar, MD

Dr. Dhar practices at Staten Island University Hospital - North Campus in Staten Island, New York.

Dr. Dhar's NPI, 1154313401, was assigned on August 22, 2005. Dr. Dhar holds New York license 218159.

Dr. Dhar's primary practice is Staten Island University Hospital - North Campus, at 475 Seaview Ave, Staten Island, NY 10305 in Richmond County. The practice phone is (718) 226-4502.

Dr. Dhar's primary practice is Staten Island University Hospital - North Campus in Staten Island, New York. Dr. Dhar is also affiliated with Staten Island University Hospital. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Dhar to 1 more hospital, 4 group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dhar practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dhar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dhar is board certified in hematology by the American Board of Internal Medicine. Dr. Dhar is licensed in New York.

CMS data shows 1,173 Medicare services from Dr. Dhar across 9 procedure codes in 2024, for 355 Medicare patients. Medicare paid $87,933 for them.

CMS counts 355 Medicare patients who saw Dr. Dhar in 2024. The largest group is 75 to 84, with 149 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dhar's median patient age at 73, with 82% women.

In 2024, Dr. Dhar wrote 621 Medicare Part D claims for 156 patients. 62% of them were for generic drugs. CMS names the drug for 485 of them, across 20 drugs with 11 or more claims each, at $2,809,451 in total drug cost. In 2023, CMS named 442 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Dhar for performance year 2024, reported through an alternative payment model (APM). Dr. Dhar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Dhar, published from 2011 to 2025. 2015 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms. Dr. Dhar has published most often in Cureus. Dr. Dhar's most frequent co-authors are Uroosa Ibrahim, MBBS, Shiksha Kedia, MD and Divya Asti, MBBS.

Dmand AI links Dr. Dhar to 2 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 8 general payments to Dr. Dhar from 7 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 70% of the total. Rigel Pharmaceuticals, Inc. paid the most, $125.